Verinurad, a uric acid transporter 1 (URAT1) inhibitor, lowers serum uric acid by promoting
its urinary excretion. Co-administration with a xanthine oxidase inhibitor (XOI) to …

To provide insight into pharmacological treatment of hyperuricemia we developed a semi‐
mechanistic, dynamical model of uric acid (UA) disposition in human. Our model represents …

Abstract Background and Objective Verinurad (RDEA3170) is a high-affinity, selective
URAT1 transporter inhibitor in development for treating gout and asymptomatic …

Objective: Renal safety risk is currently an important factor that hinders the development of
uric acid transporter 1 (URAT1) inhibitors. This study aimed to compare the renal safety and …

Introduction Hyperuricemia is a common metabolic disease, which is a risk factor for gouty
arthritis and ureteral stones and may also lead to cardiovascular and chronic kidney disease …

Aim This thorough QT/QTc (TQT) study was conducted to evaluate the risk of QT
prolongation for verinurad when combined with allopurinol. Verinurad is a novel, urate anion …

Objectives Verinurad (RDEA3170) is a high affinity, selective uric acid transporter (URAT1)
inhibitor indevelopment for treating gout and asymptomatic hyperuricaemia. This phase IIa …

Verinurad is a selective inhibitor of uric acid transporter 1 (URAT1). Here, we assessed the
safety, pharmacokinetics, and pharmacodynamics of verinurad+ allopurinol and verinurad …

Purpose Verinurad (RDEA3170) is a selective uric acid reabsorption inhibitor in clinical
development for the treatment of gout and asymptomatic hyperuricemia. The aim of this …

Background Dotinurad, a novel selective urate reabsorption inhibitor, exerts a serum uric
acid-lowering effect by selectively inhibiting urate transporter 1 (URAT1) in patients with …